Pfizer To Acquire Palo Alto-Based Anacor Pharmaceuticals
The $5.2 billion deal is expected to close in the third quarter.
The Associated Press:
Pfizer Buying Anacor Pharmaceuticals In $5.2B Deal
Pfizer will acquire Anacor Pharmaceuticals Inc. in a deal valued at about $5.2 billion. Anacor's topical treatment for eczema, called crisaborole, is currently under review by the Food and Drug Administration. If approved, Pfizer said it believes peak year sales could reach or exceed $2 billion. Anacor, based in Palo Alto, California, also holds the rights to a topical treatment for toenail fungus called Kerydin. (5/16)